Antimicrobial resistance: accelerating national and global responses

WHO strategic and operational priorities to address drug-resistant bacterial infections in the human health sector, 2025–2035

Report by the Director-General

INTRODUCTION

1. The Executive Board at its 154th session in January 2024 noted an earlier version of this report and considered the text of a draft resolution introduced by Member States.¹ The present report incorporates feedback on the draft strategic and operational priorities from Member States and partners during the session and an online consultation. The Board anticipated further informal consultations among Member States on the draft resolution during the intersessional period.

2. Antimicrobial resistance is an urgent global health and socioeconomic crisis. An estimated 1.27 million global deaths were attributed to drug-resistant bacterial infections in 2019. Antimicrobial resistance threatens all age groups in all regions, with low- and middle-income countries most affected. It has significant impacts on human and animal health, food production and the environment, and threatens the achievement of multiple Sustainable Development Goals. The World Bank estimates that, if not controlled, antimicrobial resistance will result in US$ 1 trillion to 3.4 trillion annual losses to gross domestic product (GDP) by 2030 and an additional US$ 1 trillion health care costs by 2050.

3. The development and spread of antimicrobial resistance increase the risk that common infections become impossible to treat and routine medical procedures become unsafe, including surgery and cancer treatment, thus reversing many of the gains made in modern medicine. In addition to the deaths attributable to drug-resistant infections, antimicrobial resistance is responsible for significant morbidity and disability. Antimicrobial resistance places a heavy burden on health systems and complicates the response to health emergencies.

4. Antimicrobial resistance is driven by misuse and overuse of antimicrobials. Many antimicrobials, especially antibiotics, are losing their effectiveness. There is an inadequate pipeline for new antimicrobials in research and development, and an urgent need for additional measures to ensure equitable access to new and existing antibiotics.

¹ Document EB154/13; see also the summary records of the 154th session of the Executive Board, twelfth meeting, section 4 and thirteenth meeting, section 2.
5. Antimicrobial resistance affects countries in all regions and at all income levels. Its drivers and consequences are exacerbated by poverty and inequality – for example, through unhealthy environments that enable the spread of infections; lack of access to water, sanitation and hygiene, and safe, good quality and affordable health services; and limited opportunities to make informed choices about behaviours to prevent and manage infections, especially the appropriate use of antibiotics. Changes in disease patterns, poverty and displacement of populations due to climate change are also likely to affect the emergence and spread of antimicrobial resistance. Its spread does not recognize country borders.

6. In 2015 the Sixty-eighth World Health Assembly in resolution WHA68.7 adopted the global action plan on antimicrobial resistance and urged Member States to develop and implement national action plans on antimicrobial resistance, adapted to local contexts. Since antimicrobial resistance requires a comprehensive One Health response, WHO and the other Quadripartite organizations – namely the Food and Agriculture Organization of the United Nations, the United Nations Environment Programme and the World Organisation for Animal Health – have endorsed the global action plan and are collaborating on multisectoral actions for its implementation.

7. As at November 2023, 178 countries had developed multisectoral national action plans on antimicrobial resistance. However, in 2023 only 27% of countries reported implementing their national action plans effectively and only 11% had allocated national budgets to do so.

8. An effective multisectoral One Health response to antimicrobial resistance requires strong and well-coordinated sector-specific capacities and actions. Within the human health sector, the implementation of national action plans is often fragmented and limited to hospitals, despite most antibiotic use being outside hospitals. Capacity to prevent, diagnose and treat bacterial infections and drug resistance, and the evidence base for policy development, are very limited in low- and middle-income countries. The integration of antimicrobial resistance interventions in health systems, and interdependencies with other health systems capacities and priorities, are often not recognized in strategies for universal health coverage or health emergencies.

9. In line with resolution WHA72.5 (2019) on antimicrobial resistance, in 2023 the Director-General reported to the Seventy-sixth World Health Assembly the need to accelerate the implementation of national action plans on antimicrobial resistance and proposed the development of a WHO strategic and operational framework to address drug-resistant bacterial infections in the human health sector. Each of the other Quadripartite organizations has already developed a sector-specific antimicrobial resistance strategy or flagship report, but there is not yet one for the human health sector. Ahead of the 2024 high-level meeting of the United Nations General Assembly on antimicrobial resistance, there is urgent need to articulate sector-specific priorities and actions, including to inform global and country-level discussions on targets, financing, multisectoral collaboration, governance and accountability.

---

1 Document A76/37.
10. This updated report presents urgent strategic and operational priorities for an accelerated programmatic response to antimicrobial resistance in the human health sector. The priorities complement and are informed by strategies developed by WHO regional offices.¹

11. The strategic vision underlying the development of the priorities is the control and reversal of the urgent public health and socioeconomic crisis due to drug-resistant infections in humans, as a crucial contribution to the global effort to build a healthier world for all. Based on current public health needs and recognizing that other disease-specific strategies (notably those for HIV, tuberculosis and malaria) already include actions to address drug-resistance, the specific aims are to slow the emergence and spread of drug-resistant bacterial infections and to preserve effective antibiotics, for the benefit of everyone, everywhere in current and future generations.

12. The present report proposes four urgent strategic priorities for a comprehensive public health response to antimicrobial resistance in the human health sector. The first is the prevention of all infections that give rise to the use of antibiotics, noting that viral and other infections contribute to inappropriate antibiotic use. The second strategic priority is universal access to affordable, quality diagnosis and appropriate treatment of infections. The third priority is strategic information, science and innovation – notably surveillance of both antimicrobial resistance and antimicrobial consumption/use; priority research and evidence generation to inform the response to antimicrobial resistance; the development of new vaccines, diagnostics and antimicrobial agents; and measures to make these accessible and affordable. The fourth priority is effective governance and financing of the human health sector response to antimicrobial resistance, in the context of the multi-sectoral response and a One Health approach.

13. The following sections provide the scope and guiding principles of the strategic and operational priorities and further elaborate the four strategic priorities. They describe the related operational priorities, which include a people-centred approach and core package of interventions, additional actions on governance and financing, and enabling actions to support Member States, and set out a proposed approach for measurement and accountability.

SCOPE AND GUIDING PRINCIPLES

14. The strategic and operational priorities are intended to guide efforts to tackle the causes and consequences of drug-resistant infections for people, communities and health systems. This represents a shift in focus from pathogens to health systems.

15. The priorities focus on drug-resistant bacterial infections. However, other infections, such as viral and fungal infections, may elicit the inappropriate use of antibiotics and are also considered. The pandemic of coronavirus disease (COVID-19), for example, contributed to antimicrobial resistance. As further evidence emerges on the magnitude and public health impact of drug-resistant fungal infections,² the scope of the priorities may be updated.

16. Since tackling antimicrobial resistance requires a cross-cutting public health approach, the priorities have critical linkages to Health Assembly resolutions and global strategies and plans for, inter alia, infection prevention and control; water, sanitation and hygiene; immunization; maternal and child health; diagnostics and laboratory strengthening; primary health care; universal health coverage; health

¹ See for example documents AFR/RC73/6 and EUR/RC73/7.
emergency preparedness and response; the health workforce; and disease-specific strategies such as those for HIV, tuberculosis, malaria and sexually-transmitted infections.

17. The operational priorities comprise (i) implementation at country level of the people-centred approach to addressing antimicrobial resistance in human health and its accompanying WHO core package of interventions to support national action plans; (ii) additional country and global actions on governance and financing, and (iii) enabling actions to support Member States. The people-centred approach was developed by means of extensive review of evidence, including data from annual Tracking AMR Country Self-assessment Surveys (TrACSS) in over 170 countries and the Global Antimicrobial Resistance and Use Surveillance System (GLASS). It was also informed by feedback from a global consultation with Member States and other stakeholders, and expert opinion including input from WHO’s Strategic and Technical Advisory Group for Antimicrobial Resistance.

18. Guiding principles throughout this document include, but are not limited to, access, equity, efficiency, scalability, sustainability, accountability; addressing common and specific needs for all income settings; integration of priority actions at all levels of health systems; inclusivity, both to address the needs of marginalized or vulnerable groups and to recognize the contributions of diverse stakeholders including civil society and the private sector; and solidarity to address a global threat, including the role that more affluent countries must play.

STRATEGIC PRIORITIES

19. The first three strategic priorities – prevention of infections; universal access to affordable, quality diagnosis and appropriate treatment; and strategic information, science and innovation – represent interdependent elements of a comprehensive public health approach for sustained impact in slowing the emergence and spread of drug-resistant bacterial infections and preserving effective antibiotics. The effective governance and financing priority reinforces cross-cutting and enabling functions across these first three priorities, including leadership, governance, financing, regulation, accountability, advocacy, and education, awareness-raising and behaviour change among both health professionals and communities.

20. **Prevention of infections.** The objective for this priority is to reduce all infections which may result in antibiotic use. This has a direct public health impact on morbidity and mortality and will reduce the emergence and spread of antimicrobial resistance. It requires accelerated implementation of water, sanitation and hygiene measures both in health facilities and communities; infection prevention and control and patient safety; and immunization.

21. **Universal access to affordable, quality diagnosis and appropriate treatment of infections.** To reduce morbidity and mortality caused by infections while reducing the inappropriate use of antibiotics, people need access to quality diagnosis and appropriate treatment of both susceptible and drug-resistant infections at all levels of the health system. In the context of overall efforts to strengthen health systems and expand access to health services through the primary health care approach, while reducing financial hardship, this priority requires integration of specific interventions – notably for diagnostic and antibiotic stewardship based on WHO’s AWaRe (access, watch, reserve) classification and The WHO AWaRe antibiotic book. It includes ensuring gender-equitable access and addressing the specific needs of vulnerable groups including migrants and refugees, and awareness-raising and education among health workers and the public.

22. **Strategic information, science and innovation.** To guide and support the response to antimicrobial resistance by ensuring the availability of key evidence, policies, and products, crucial
information and evidence gaps must be filled, especially in low- and middle-income countries, and measures taken to address critical gaps in research and development and access for antibiotics, diagnostics and vaccines. This priority therefore includes strengthening and improving the surveillance of antimicrobial consumption and antimicrobial resistance, including through national antimicrobial resistance prevalence surveys; promoting evidence generation and priority research agendas both globally and at country-level to inform policy development; comprehensive measures to promote increased research and development for vaccines, diagnostics and antibiotics (and alternatives) targeted to greatest public health needs; the introduction of programmatic innovations such as genomic surveillance, point-of-care diagnostics and digital health solutions; and regional and global mechanisms to overcome pipeline, production, distribution and access bottlenecks.

23. **Effective governance and financing of the human health sector response to antimicrobial resistance.** This priority is crucial for progress across the other three strategic priorities. It is focused on ensuring leadership and resources for efficient and effective implementation of the human health sector elements of multi-sectoral national action plans on antimicrobial resistance, as well as integration of antimicrobial resistance priorities and activities in overall health sector planning and financing – especially in strategies for primary health care, universal health coverage, and health emergency preparedness and response. This must also complement other awareness-raising and education, and ensure an inclusive approach which recognizes and provides an enabling framework for the contributions, and needs, of diverse stakeholders across the public and private sectors, civil society, the health and care workforce, and communities.

**OPERATIONAL PRIORITIES**

**The people-centred approach and core package of country-level interventions**

24. The people-centred approach to antimicrobial resistance summarizes the country-level actions needed to operationalize the four strategic priorities. It emphasizes an integrated programmatic approach, aligned with strategies for primary health care, universal health coverage and health emergency preparedness and response, that covers all levels of the health system.

25. This approach puts people at the centre of antimicrobial resistance interventions, based on a root-cause analysis of both “system challenges” and “people’s challenges” (Fig. 1). It also emphasizes inclusive engagement of communities, health and care workers, civil society, academia and stakeholders across the public and private sectors.

26. The people-centred approach to antimicrobial resistance and its package of core interventions includes four programmatic pillars plus strategic information and effective governance as essential foundations (Table 1). When developing or revising their national action plans on antimicrobial resistance, countries can use the package of interventions to identify gaps, inform prioritization at different levels of the health system and guide the integration of interventions in national health sector plans and strategies.

27. The pillars and core interventions of the approach constitute the proposed operational priorities for addressing drug-resistant bacterial infections in countries. Full implementation of the approach will

---

slow the emergence and spread of antimicrobial resistance and reduce the associated morbidity, mortality and wider socioeconomic impact.
Fig. 1. System and people’s challenges for antimicrobial resistance

**System challenges**
- Limited health worker education on antimicrobial resistance
- Poor water, sanitation and safe waste management
- Poor infection prevention and control programmes and practices
- Weak immunization programmes
- Limited health service coverage and lack of financial protection for the entire population
- Lack of sufficient health care services, diagnostics and antimicrobials and trained health workers
- Use of substandard or falsified diagnostics and antimicrobials
- Weak referral systems
- Weak regulation of over-the-counter medicines
- No quality-assured treatment, standardized treatment guidelines or stewardship
- Inappropriate prescribing of antimicrobials

**People’s challenges**
- Poor health education
- No access to clean water or sanitation
- Poor adherence to practices to prevent transmission of infection
- Poor access or missed vaccinations and vaccine hesitancy
- Catastrophic out of pocket spending on health services, diagnostics or medicines
- Poor access to and lack of awareness of available local health services
- Loss to follow-up
- Incorrect or delayed diagnosis
- Poor access to local diagnostic services
- Limited awareness of the importance of timely, accurate diagnosis
- Inappropriate self-medication (e.g. use of over-the-counter or leftover antimicrobials, incomplete treatment cycle)
- Increased risk of suboptimal treatment, leading to complications or longer recovery
- Higher risk of morbidity or mortality due to infections that are difficult to treat or untreatable
Table 1. Strategic priorities and the people-centred approach to antimicrobial resistance

<table>
<thead>
<tr>
<th>Strategic priorities</th>
<th>Pillars/foundations of the people-centred approach</th>
<th>Core interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention</td>
<td>Prevention</td>
<td>• Universal access to water, sanitation and hygiene and waste management</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Implementation of core infection prevention and control components</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Access to vaccines and expanded immunization</td>
</tr>
<tr>
<td>Universal access</td>
<td>Access to essential health services</td>
<td>• Antimicrobial resistance diagnosis and management health services made available and affordable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Uninterrupted supply of quality-assured, essential antimicrobials and health products for antimicrobial resistance</td>
</tr>
<tr>
<td>Timely, accurate diagnosis</td>
<td>Support for strategic information foundation</td>
<td>• Good quality laboratory system and diagnostic stewardship to ensure clinical bacteriology (and mycology) testing</td>
</tr>
<tr>
<td>Appropriate, quality-assured treatment</td>
<td></td>
<td>• Up-to-date evidence-based treatment guidelines and programmes for antimicrobial stewardship</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Regulation to restrict sales of non-prescription antimicrobials</td>
</tr>
<tr>
<td>Strategic information, science and innovation</td>
<td>Strategic information foundation</td>
<td>• National antimicrobial resistance surveillance network to generate good quality data for patient care and action on antimicrobial resistance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Surveillance of antimicrobial consumption and use to guide patient care and action on antimicrobial resistance</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Antimicrobial resistance research and innovation including behaviour and implementation science</td>
</tr>
<tr>
<td>Governance and financing</td>
<td>Effective governance foundation</td>
<td>• Antimicrobial resistance advocacy, governance and accountability in the human health sector, in collaboration with other sectors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Antimicrobial resistance awareness-raising, education and behaviour change of health workers and communities</td>
</tr>
</tbody>
</table>

Additional country and global actions on governance and financing

28. Member States have the primary responsibility to develop, cost, finance, implement and monitor their antimicrobial resistance national action plans. In addition to the effective governance foundation in the people-centred approach, this requires commitment, leadership and accountability at the highest levels of government – both to address antimicrobial resistance through a One Health approach and to champion and take forward the human health sector-specific priorities detailed in this report. For example, in some countries responsibility for antimicrobial resistance coordination is via a cabinet-level ministerial committee or office of the deputy president or prime minister.

29. Recognizing the public health and socioeconomic consequences of antimicrobial resistance, the current lack of dedicated national budgets for implementation of national action plans in almost all countries, and increasing evidence for the compelling investment and economic case for addressing antimicrobial resistance, Member States are encouraged to integrate the people-centred approach and core interventions in overall health sector planning and financing. They should ensure coherence with the contributions of other health sector plans and strategies for addressing antimicrobial resistance, and allocate additional domestic resources where needed and feasible.
30. In addition, there is an important role for international aid and other external financing and partnerships. For example, over 80% of approved first-round Pandemic Fund grants to countries include antimicrobial resistance activities, and, as at February 2024, 25 countries have included relevant antimicrobial resistance activities in their Global Fund applications.

31. Specific efforts including existing and new international financing and innovative partnerships are especially important to address the antibiotic pipeline and access crisis, and other science and research and development needs in the third strategic priority.

Enabling actions to Support Member States

32. The Secretariat supports countries on all aspects of the antimicrobial resistance response, through country-level technical assistance tailored to local context including for fragile, conflict-affected and vulnerable settings, and coordination of global or regional action and partnerships.

33. Noting Member States’ increased demands for technical support, the Secretariat is developing a global AMR Technical Assistance Mechanism; initiatives to address specific needs, for example the AMR Diagnostic Initiative; and targeted guidance and educational materials.

34. The Secretariat also supports countries to identify and mobilize domestic and external financing, such as through the Global Fund and the Pandemic Fund, and supports development of global and country-specific antimicrobial resistance investment cases.

35. The evidence base on antimicrobial resistance is very weak in most countries. The Secretariat supports generation, reporting and use of surveillance and research data, such as through the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) and nationally representative antimicrobial resistance prevalence surveys, aligned with country-specific priorities and WHO’s global research agenda for antimicrobial resistance in human health.

36. With industry and relevant partner organizations, the Secretariat will monitor, inform and promote global research and development efforts targeted to priority pathogens and greatest public health needs, and develop mechanisms to support equitable, sustainable access to new and existing antibiotics alongside other needed health products such as vaccines, diagnostics and reagents. Examples of the diverse and tailored solutions needed include coordinated/pooled procurement, strategic stockpiling, improved forecasting and quantification, regulatory streamlining and expanded manufacturing.

37. To enhance commitment, action and resource mobilization to tackle antimicrobial resistance, and drawing on behavioural insights and other relevant evidence, the Secretariat will coordinate international advocacy, education and awareness-raising with key partners and networks – for example with policy-makers, legislators, health care providers and civil society, including youth and antimicrobial resistance survivors.

MONITORING AND TARGETS

38. To monitor implementation and progress, the Secretariat will, in consultation with all stakeholders, continue to develop a measurement and accountability framework, which may potentially include global targets, as discussed with Member States at the 154th session of the Executive Board.
39. Potential indicators for the strategic priorities are listed in Table 2. The Secretariat plans to publish potential indicators for the vision, aim and operational priorities online for consultation with Member States and other stakeholders in April–May 2024.¹

40. Relevant outputs and indicators will be included in the measurement framework for WHO’s fourteenth general programme of work.

41. The priorities and ongoing development of the measurement and accountability framework will inform Member States deliberations, and potential development of global targets, for the 2024 high-level meeting of the United Nations General Assembly on antimicrobial resistance and the Fourth High-level Ministerial Meeting on Antimicrobial Resistance which Saudi Arabia plans to host in November 2024.

42. The measurement and accountability framework can be used to inform context-specific target-setting by countries, informed by both quantitative and qualitative strategic information.

Table 2. Potential indicators for the strategic priorities

<table>
<thead>
<tr>
<th>Strategic priorities</th>
<th>Potential indicators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of infections</td>
<td>• Relevant existing indicators for WaSH in health care facilities (WHO/UNICEF), immunization (Immunization Agenda 2030) and infection prevention and control (WHO global strategy on infection prevention and control)</td>
</tr>
</tbody>
</table>
| Universal access to affordable, quality diagnosis and appropriate treatment of infections | • Coverage of essential health services (SDG indicator 3.8.1)  
• Financial protection (SDG indicator 3.8.2)  
• Proportion of population seeking care in health care facilities with access to quality-assured bacteriology diagnosis  
• Antibiotic consumption in defined daily dose per 1000 inhabitants per day; overall and by AWaRe (access, watch, reserve) classification. (Note: this indicator is influenced by both access and appropriate use, so cannot be interpreted in isolation.) |
| Strategic information, science and innovation | • Number/proportion of countries with, and proportion of world’s population covered by, nationally representative quality-assured antimicrobial resistance data from surveillance and/or surveys  
• Number of new (i) medicines, and (ii) diagnostics in the research and development pipeline aligned with WHO target product profiles and bacterial priority pathogens list |
| Governance and financing | • Number/proportion of countries in which national action planning on antimicrobial resistance is integrated with the National health sector plan (reported annually in Tracking AMR Country Self-Assessment Surveys (TrACSS))  
• Number/proportion of countries in which (i) national antimicrobial resistance action plan has a costed and budgeted operational plan and has a monitoring mechanism in place, and (ii) financial provision for the national antimicrobial resistance action plan implementation is included in the national plans and budgets (reported in TrACSS) |

ACTION BY THE HEALTH ASSEMBLY

43. The Health Assembly is invited to note the report.

¹ The potential indicators will be available at the following link: https://www.who.int/news-room/articles-detail/consultation-monitoring-framework-strategic-and-operational-priorities-to-address-drug-resistant-bacterial-infections.